Cellipont Bioservices, a cell therapy CDMO, and Mongoose Bio, a clinical-stage biopharma company pioneering next gen precision T-cell based therapies targeting solid cancers, signed an agreement for the technology transfer, process development, and cGMP manufacture of its autologous MGB-001 TCR-T cell therapy program.   Mongoose Bio will leverage its antigen discovery pipeline and advanced memory T cell reprogramming technology to help address both common and rare solid tumors, delivering sust...